REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, September 12 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today the company's Chief Scientist Prof. Zvi Bentwich will present AACR's upcoming Molecular Diagnostics in Cancer Therapeutic Development conference. Prof. Bentwich's presentation will focus on Rosetta Genomics unique microRNA-based technologies and current development programs. The event will take place at the Atlanta Hilton, Atlanta.
The presentation, titled, "Human microRNAs: Powerful Biomarkers for Cancer Diagnostics", is part of a plenary session on the molecular classification of tumors, which will be held on Wednesday, September 19, between 10:45 am-1:00 pm.
An audio webcast of the presentation will be made available by AACR 15 days after the conference at the following url: http://www.aacr.org/home/scientists/meetings--workshops/molecular-diagnosti c s-in-cancer-therapeutic-development.aspx
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
About Rosetta Genomics
Rosetta Genomics (Nasdaq:ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and various diseases. For more information please visit: http://www.rosettagenomics.com
|SOURCE Rosetta Genomics Ltd|
Copyright©2007 PR Newswire.
All rights reserved